Monoclonal antibodies (MA) were produced by hybridomas obtained through the fusion of mouse myeloma cells with lymphocytes obtained from the spleens of mice or rats immunized against a variety of human tumour antigens. Of the 11 MA that bind in radioimmunoassay (RIA) to human melanoma, 3 recognize the DR antigen, which is also expressed by human lymphocytes, 1 recognizes an antigen that is also expressed by some astrocytomas but not by any other cells and 6 define antigens expressed only by melanomas; 7 of these immunoprecipitate antigens of different mol. wts. Of 11 MA that bind to colorectal carcinoma (CRC), 1 defines carcinoembryonic antigen (180,000 mol. wt), 3 bind to a monosialoganglioside that can be isolated from CRC and meconium but not from other tissue, 3 react with neutral glycolipids extracted from CRC, and 2 immunoprecipitate a CRC antigen with mol. wt 21-28,000; 1 of these MA effectively suppresses the growth of CRC in nude mice. MA have also been raised through the immunization of animals with cells from astrocytoma, lung adenocarcinoma, lung oat-cell carcinoma and breast carcinoma; identification of the antigens recognized by these MA is still in pr-elimninary stages. TWO Seven supernates showed strong specific fluorescence against such components of normal human colonic mucosa as smooth muscle, goblet-cell mucin and epithelium. There were several different patterns of epithelial fluorescence, which depended on the antibody and the site from which the sample of mucosa was taken. None of the antibodies gave the same pattern, whilst all were consistent.
Activity on the corresponding colonic carcinoma was generally less than that on normal mucosa, or absent. One supernate showed enhanced antitumour activity and was also active against a crude extract of CEA. No supernate gave fluorescence with tumour and was inactive on normal colon.
Immunofluorescence and other histochemical techniques a,re available for separating different antibody activites again,st complex tissue antigens, and w%ill help define the possible application of these antibodies. internally labelled with 3H-lysine, and their antibody activity against a variety of membrane preparations determined. Nine human monoclonal antibodies were found which bound to molecules on lung-cancer membranes but not to those found in normal lung membranes from the same patient. The determinants against which these antibodies were directed were found on lung tumours from several different patients.
MONOCLONAL ANTIBODIES TO
The abstract which occupied this space was withdrawn at the last minute. A number of monoclonal antibodies to EBVtransformed B cells have been raised in rats. Some of these monoclonal antibodies were shown to be lymphoma-cell specific, in that they only reacted with in vitro cultured cell lines derived from patients with Burkitt's lymphoma. These same monoclonal antibodies failed to react with EBV-transformed lymphoblastoid cell lines and with normal lymphocytes. The lymphoma-specific monoclonal antibodies did not distinguish between EBV-and EBV+ lymphoma lines.
HUMAN MONOCLONAL ANTIBODIES
A monoclonal antibody to the HLA-DR locus was also described. The determinant recognized by this antibody is monomorphic in man but polymorphic in mic studies with inbred recombinan mice show that this antigen is with H-2 haplotypes B, D and Q, for by genes within the IA submonoclonal antibody was found tate 3 polypeptide chains frc labelled Raji cells. These inclue pected 34,000 dalton and 28,000 ( peptides, as well as a third co 25,000 dalton. Tumour-bearing mice were injected i.v. with equal amounts of 1251I-labelled specific monoclonal antibody (LICR-LON/HT13) and 1311-labelled normal mouse IgG or nonspecific monoclonal IgG simultaneously. At intervals of up to 4 days after injection, the animals were killed and radioactivity in blood, tumours and organs was counted.
It was found that the specific antibody localized in the tumours between 17 (liver) and 50 (muscle) times higher than normal mouse tissues. Tumour/blood ratios reached in excess of 10, 96 h after injection. Tumour weight was important, in that the smaller the tumour, the better the localization. The antiteratoma antibody was also shown to localize in vivo in 4 additional human germ-cell tumour xenografts but not in non-germ-cell tumours.
Autoradiography showed that the injected specific monoclonal antibody was localized to viable parts of the tumour and in close association with the tumour-cell surfaces.
Our studies therefore have shown for the first time, that monoclonal antibodies are capable of human tumour-xenograft localization in vivo. On the basis of these results we are extending this approach to clinical studies.
